Idebenone for the Preventive Treatment of Migraine
Condition(s) studied
Investigational drug(s) / intervention(s)
Placebo: Placebo oral tablet, three times a day
90mg Idebenone: Idebenone 30 MG Oral Tablet, three times a day
270mg Idebenone: Idebenone 90 MG Oral Tablet, three times a day
Study summary
Idebenone improves energy metabolism similarly to Coenzyme Q10, which is effective in migraine prophylaxis. The investigators compare idebenone (90 mg/day, 270 mg/day) and placebo in 180 migraine patients in a double-blind, randomized, placebo-controlled, multicenter trial to study whether Idebenone is superior to placebo in the prevention of episodic migraine with or without aura.
Eligibility
Primary outcome measure(s)
- The change of migraine attack frequency — month 0, month 1, month 2, month 3, month 4
The change of migraine attack frequency in month 4 compared with baseline. Headache data (e.g., occurrence, duration, and pain severity; occurrence of photophobia, phonophobia, nausea, or vomiting; and any use of migraine medication) were captured daily through a daily headache-diary. Degree of pain and results of treatment are scored by visual analogue scale(VAS).
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Kaiming Liu | Hangzhou | Zhejiang | Recruiting |
More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04151472 on ClinicalTrials.gov ↗ ← All trials in China